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Background-—Cardiac amyloidosis is a fatal disease whose prognosis and treatment rely on identiﬁcation of the amyloid type. In
our aging population transthyretin amyloidosis (ATTRwt) is common and must be differentiated from other amyloid types. We
report the clinical presentation, natural history, and prognostic features of ATTRwt compared with cardiac-isolated AL amyloidosis
and calculate the probability of disease diagnosis of ATTRwt from baseline factors.
Methods and Results-—All patients with biopsy-proven ATTRwt (102 cases) and isolated cardiac AL (36 cases) seen from 2002 to
2011 at the UK National Amyloidosis Center were included. Median survival from the onset of symptoms was 6.07 years in the
ATTRwt group and 1.7 years in the AL group. Positive troponin, a pacemaker, and increasing New York Heart Association (NYHA)
class were associated with worse survival in ATTRwt patients on univariate analysis. All patients with isolated cardiac AL and 24.1%
of patients with ATTRwt had evidence of a plasma cell dyscrasia. Older age and lower N-terminal pro-B-type natriuretic peptide (NT
pro-BNP) were factors signiﬁcantly associated with ATTRwt. Patients aged 70 years and younger with an NT pro-BNP <183 pmol/L
were more likely to have ATTRwt, as were patients older than 70 years with an NT pro-BNP <1420 pmol/L.
Conclusions-—Factors at baseline associated with a worse outcome in ATTRwt are positive troponin T, a pacemaker, and NYHA
class IV symptoms. The age of the patient at diagnosis and NT pro-BNP level can aid in distinguishing ATTRwt from AL amyloidosis.
( J Am Heart Assoc. 2013;2:e000098 doi: 10.1161/JAHA.113.000098)
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W ithout effective treatment cardiac amyloidosis is a fataldisease. There are 3 major amyloid types that affect
the heart: light-chain (AL) amyloidosis, hereditary transthyretin
amyloidosis (ATTRm), and wild-type transthyretin amyloidosis
(ATTRwt), also known as senile cardiac amyloidosis.1–3
Correctly identifying the amyloid type is vital, as it has a major
impact on prognosis and completely dictates treatment. Biopsy
followed by Congo Red staining and immunohistochemistry is
the gold standard for diagnosing and typing amyloid.4 Correct
diagnosis of isolated cardiac amyloidosis clinically is especially
challenging as symptoms are often nonspeciﬁc. The diagnosis
of ATTRm is relatively straightforward if genetic screening of
the TTR gene is performed, but differentiating between ATTRwt
and AL amyloidosis can be more problematic. ATTRwt invari-
ably affects older patients, who may well have an incidental
monoclonal gammopathy of undetermined signiﬁcance
(MGUS). If the coexistence of amyloidosis and a plasma cell
dyscrasia alone is used as evidence of AL amyloidosis,
chemotherapy-based treatment may be given in error.5
Recent advances in cardiac magnetic resonance imaging
(MRI) have led to a dramatic increase in detection of late
gadolinium enhancement, which is reported to be charac-
teristic of amyloidosis. Some features appear more char-
acteristic of ATTR amyloid such as transmural late
gadolinium enhancement (LGE) and right ventricular LGE,
but currently MRI appearances cannot differentiate between
amyloid types.6 ATTRwt amyloidosis is almost certainly
underdiagnosed,7 and as the prevalence increases with age
and the population demographic shifts toward the elderly, the
burden of disease will become an increasing problem.8,9
From the National Amyloidosis Centre (J.H.P., C.J.W., J.D., S.M.B., P.S., A.W.,
S.D.J.G., C.P.V., N.W., C.A.M., J.A.G., D.R., P.N.H., J.D.G., H.J.L.) and UCL
Centre for Nephrology (J.H.P., J.D.G., H.J.L.), UCL Medical School, Royal Free
Hospital, London, UK; Biostatistics Unit, UCL Eastman Dental Institute, London,
UK (A.P.); St George’s Hospital University of London, London, UK (J.D.); The
Heart Hospital UCLH United Kingdom, London, UK (S.M.B.).
Correspondence to: Jennifer H. Pinney, MRCP, UK National Amyloidosis
Centre, UCL Division of Medicine, Royal Free Hospital, Rowland Hill Street,
London, NW3 2PF, UK. E-mail: j.pinney@ucl.ac.uk
Received October 3, 2012; accepted February 5, 2013.
ª 2013 The Authors. Published on behalf of the American Heart Association,
Inc., by Wiley-Blackwell. This is an Open Access article under the terms of the
Creative Commons Attribution Noncommercial License, which permits use,
distribution and reproduction in any medium, provided the original work is
properly cited and is not used for commercial purposes.
DOI: 10.1161/JAHA.113.000098 Journal of the American Heart Association 1
ORIGINAL RESEARCH
Currently there is no speciﬁc licensed treatment for
ATTRwt amyloidosis, but new drugs are on the horizon, with
several clinical trials currently recruiting patients with trans-
thyretin amyloidosis (http://clinicaltrials.gov/ct2/results?
term=transthyretin). Deﬁning the clinical course of the
disease is important both for patient counseling for a disease
for which there is currently limited literature and to identify
clinical diagnostic and response criteria for further treatment
trials.10,11
Here we report the clinical presentation of 102 patients
with ATTRwt seen at the UK amyloid referral center between
2002 and August 2011 and compare them to 36 patients with
isolated cardiac AL amyloidosis. We describe the natural
history of the disease and identify baseline factors that are
associated with poor survival. By comparing patients with
ATTRwt and isolated cardiac AL amyloidosis, we have created
a model to calculate the probability of a diagnosis of ATTRwt
amyloidosis. From this model we have designed a diagnostic
algorithm that can help to guide a diagnostic approach.
Methods
Patients
We analyzed all 102 patients with biopsy-conﬁrmed ATTRwt
diagnosed between 2002 and August 2011 at a single UK
center and compared them with the 36 patients with biopsy-
conﬁrmed isolated cardiac AL amyloidosis diagnosed over the
same period at the same center.
Patients were referred from throughout the United
Kingdom and Ireland. All referrals were accepted irrespective
of the previous investigations or prior evidence of amyloid. In
the AL group, 20 patients were referred from cardiology, and
16 patients were referred by hematologists; all AL patients
had been seen by a cardiologist before initial assessment at
our center. In the ATTRwt group, 73 patients were referred
from cardiology, 18 from hematology, 3 from general
practice, 2 each from gastroenterology and urology, and 1
each from elderly care, neurology, rheumatology, and
respiratory medicine. Ninety-three of the 102 patients in
the ATTRwt group had been seen before referral by a
cardiologist.
At our center all patients had an initial diagnostic
assessment that included clinical evaluation, ECG, echocar-
diogram, serum amyloid P component (SAP) scintigraphy,
and biochemical evaluation. Onset of symptoms was deﬁned
on the basis of the history, but a diagnosis of amyloidosis
was dated from the biopsy, which provided histological proof
of amyloid. If necessary after our initial assessment, advice
was given to the referring doctor regarding further investi-
gations required to conﬁrm the diagnosis histologically.
Patients were then reviewed at 6 to 12 monthly intervals.
Follow-up assessment comprised clinical and biochemical
evaluation, ECG, and echocardiogram. N-terminal pro-B-type
natriuretic peptide (NT pro-BNP) concentration was mea-
sured in all patients presenting after 2007. In patients
diagnosed earlier, NT pro-BNP was measured on banked
serum samples that had been kept at 30°C. Evidence of a
plasma cell dyscrasia was deﬁned as any of the following:
detectable M-protein on plasma electrophoresis or immuno-
ﬁxation, Bence Jones proteins in urine, or abnormal serum
free light-chain level (kappa >19.4, lambda >26.3) or
abnormal ratio (0.26 to 1.65).
The study was approved by the Ethics Committee of the
Royal Free Hospital, and patients provided informed consent.
Diagnostic Procedures
Amyloid deposition was conﬁrmed histologically in all
patients; sections from formalin-ﬁxed, parafﬁn-embedded
biopsy specimens were stained with Congo Red and viewed
under cross-polarized light.4 Immunohistochemical staining
of amyloid deposits was performed using monospeciﬁc
antibodies reactive with SAA, kappa, lambda, and transthy-
retin as previously described.12 A diagnosis of AL amyloido-
sis was only made if there was positive kappa or lambda
immunohistochemical staining of amyloid in endomyocardial
tissue. All the ATTRwt patients had immunohistochemical
conﬁrmation of transthyretin amyloidosis from a variety of
tissues.
All patients with transthyretin amyloidosis were conﬁrmed
to be wild type on genotyping. Genomic DNA was extracted
from whole blood treated with EDTA.13 The coding regions of
the transthyretin gene were ampliﬁed by polymerase chain
reaction assay. Exons 2, 3, and 4 of the TTR gene were
sequenced as previously described.14
All patients had amyloidotic cardiomyopathy deﬁned by
either endomyocardial biopsy proof of amyloid deposition or a
mean left ventricular wall thickness (septum and posterior
wall) >12 mm in the absence of hypertension or other causes
of left ventricular hypertrophy, consistent with published
consensus criteria for AL amyloidosis.15 As there is currently
no published consensus for ATTR amyloid, the same criteria
were used.
Signiﬁcant systemic amyloidosis was excluded by whole-
body anterior and posterior scintigraphic imaging after
administration of 123I-labeled SAP using an Elscint Superhelix
gamma camera was undertaken at baseline.16
Instrumental Deﬁnitions
ECG measures were based on standard deﬁnitions.17 Echo-
cardiographic measures of chamber quantiﬁcation were based
on standard recommendations.18 In the survival analysis left
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ventricular wall thickness was graded as mild 1.3 to 1.5 cm,
moderate 1.6 to 1.9 cm, and severe >2.0 cm. Ejection
fraction was graded as normal >55%, mild impairment 45% to
54%, moderate impairment 36% to 44%, and severe impair-
ment <35%.
Classiﬁcation of diastolic dysfunction on echocardiography
was based on published data.19 Not all patients were included
in the classiﬁcation of diastolic dysfunction because of lack of
measured parameters in patients diagnosed before 2005.
Statistical Analysis
Results are expressed as mean (SD), median (Q1, Q3), or
percentage as appropriate. Patient follow-up was censored at
the last clinic visit. Univariate analysis compared the baseline
data in the 2 groups used the unpaired t test (if the data were
normally distributed) and the nonparametric Mann–Whitney
test for numerical variables and the chi-square or Fisher exact
test for categorical variables. Factors that achieved statistical
signiﬁcance (P<0.05) and were deemed clinically relevant
were included in a multivariable logistic regression model
(SPSS Statistics version 19).
Patient survival was estimated by Kaplan–Meier analysis
(Stata version 11; StataCorp LP). The log-rank test was used
to compare differences in stratiﬁed Kaplan–Meier survival
curves. Cox regression analysis using a backward stepwise
approach was used to investigate factors associated with
overall survival in ATTRwt patients, using IBM SPSS Statistics
(version 19); statistical signiﬁcance was achieved if P<0.05.
Results
Referral Patterns and Diagnosis
Of the 102 diagnosed with ATTRwt; 65 (63.7%) were
diagnosed on endomyocardial biopsy, 24 (23.5%) on gastro-
intestinal biopsy, 4 (3.9%) from bladder biopsy, 4 (3.9%) on fat
biopsy, 1 (0.9%) on carpal tunnel biopsy, and 1 (0.9%) from
fallopian tube tissue. Fifteen patients (41.6%) in the AL group
and 46 patients (46.5%) in the ATTRwt group had amyloid
proven on a biopsy before the initial assessment. The initial
investigation that prompted the referral or biopsy in the AL
group was echocardiogram in 22 (61.1%), cardiac magnetic
resonance (CMR) imaging in 12 (33.35%), and bone marrow
and CT scan in 1 each. In the ATTRwt group the initial
investigation that prompted referral or biopsy was echocar-
diogram in 55 (55.5%), CMR in 37 (37.4%), cystoscopy in 2
cases, and colonoscopy, gastroscopy, and cardiomegaly on
chest x-ray in 1 each. Two cases were referred on the basis of
evidence of a plasma cell dyscrasia and a history of
breathlessness. Thirty-six of a total of 1953 patients with AL
amyloidosis diagnosed with isolated cardiac AL amyloidosis
after comprehensive evaluation represented 1.84% of AL
patients.
The number of diagnoses of ATTRwt has increased in the
past 5 years, with a doubling in the last 12 months, whereas
the numbers of patients with isolated cardiac AL amyloidosis
has remained the same (data not shown). In the ATTRwt group
from 2007 to 2011, 75% to 80% of referrals each year were
from cardiologists.
Baseline Characteristics
Features in the history
Three patients did not have evidence of cardiac amyloid on
echocardiography. These were patients with amyloid in tissue
from the gastrointestinal tract, bladder, and carpal tunnel;
these patients were therefore removed from further analyses.
Baseline (initial assessment) patient demographics of both
groups can be seen in Table 1. ATTRwt is a predominantly
male disease; 88.8% of affected patients were men, signiﬁ-
cantly higher than the 69.4% of cardiac AL patients. The
median age at presentation was 73 years, signiﬁcantly older
than the 63 years in cardiac AL. Presenting symptoms were
similar in both groups, with the majority reporting breath-
lessness. The severity, however, was greater in the AL group,
with more patients describing New York Heart Association
(NYHA) class III/IV symptoms and >50% of ATTRwt patients
describing NHYA class I/II symptoms. The variety of present-
ing symptoms was much wider in the ATTRwt group than
among the AL patients. A history of arrhythmia was common;
43.4% had a history of atrial ﬁbrillation (AF), which was the
presenting complaint in 10% of patients. AF was more
common in the ATTRwt group than among the AL patients.
Eight percent of ATTRwt patients were found to have amyloid
incidentally on routine testing or at the time of an operation
for a different complaint; this feature was not seen in AL
amyloidosis. TTR patients diagnosed by cardiac biopsy as
opposed to other tissues were younger (median age at
diagnosis, 72 versus 77 years; P≤0.01), with a lower NT pro-
BNP (median, 295 versus 540 pmol/L; P=0.03). Although
there was a higher mitral valve E/A ratio (median 2.7 versus
1.6; P=0.01) in the cardiac biopsy group all other measures of
diastolic dysfunction (IVRT, E/E , and mitral valve deceleration
time) were not signiﬁcantly different, implying no real
difference in overall diastolic function.
A history of carpal tunnel syndrome was signiﬁcantly more
common in the ATTRwt group than in the AL group (48.5%
versus 8.3%); in the AL group 2 patients had symptoms of
carpal tunnel at the time of diagnosis, and 1 had a release a
year before diagnosis. In the ATTRwt group 12 patients had
symptoms of carpal tunnel syndrome at the time of diagnosis,
and 40 had previous release operations a median of 8 years
(Q1, Q3: 3, 10 years) before diagnosis.
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Table 1. Baseline Patient Characteristics
AL (n=36) ATTRwt (n=99) P Value
Male, n (%) 25 (69.4) 88 (88.8) 0.01
Age at diagnosis, years (Q1, Q3) 63.0 (56.6, 65.8) 73.0 (69.5, 78.2) <0.001
Age at symptom onset, years (Q1, Q3) 60.2 (53.8, 65.2) 70.9 (67.7, 74.1) <0.001
Age at death (Q1, Q3) 63 (56, 67) 77 (74, 81) <0.001
NT pro-BNP, pmol/L (Q1, Q3) 714.0 (427.5, 1573.0) 317.5 (212.3, 909.3) <0.001
NT pro-BNP (age ≤70), pmol/L (Q1, Q3) 633 (412, 1073) 293 (227, 404)
NT pro-BNP (age >70), pmol/L (Q1, Q3) 2127 (1498, 2755) 440 (244, 794)
Troponin T, ng/mL (Q1, Q3) 0.05 (0.02, 0.1) 0.04 (0.02, 0.05) 0.3
Positive troponin T, n (%) 19 (52.7) 51 (51.5)
Hb, g/dL (Q1, Q3) 13 (12.4, 13.6) 14.8 (12.8, 14.8) 0.005
Albumin, g/L (Q1, Q3) 41 (39, 43) 44 (41.3, 46.0) <0.001
Bilirubin, lmol/L (Q1, Q3) 14 (11, 24) 15 (13, 28) 0.2
ALP, U/L (Q1, Q3) 95 (72, 148) 106 (77, 138) 0.5
GGT, U/L (Q1, Q3) 75.5 (41.0, 142.3) 111.0 (71.0, 162.3) 0.1
eGFR, mL/min (Q1, Q3) 64 (48, 87) 63 (41, 69) 0.2
24-Hour urine protein, g (Q1, Q3) 0.39 (0.1, 0.8) 0.1 (0.1, 0.2) <0.001
Lambda free light chain, mg/L (Q1, Q3) 255 (116, 468) 16 (13, 21) <0.001
Missing, n (%) 0 (0) 8 (8)
Kappa free light chain, mg/L 31 (7, 22) 18 (14, 24) 0.01
Missing, n (%) 0 (0) 8 (8)
Detectable paraprotein (%) 24 (66) 14/93 (15) <0.001
Missing, n (%) 0 (0) 6 (6)
Any detectable plasma cell dyscrasia,* n (%) 36 (100) 22/91 (24%) <0.001
Missing, n (%) 0 (0) 8 (8)
Supine systolic blood pressure, mm Hg (Q1, Q3) 107 (95, 118) 116 (107, 134) 0.006
Supine diastolic blood pressure, mm Hg (Q1, Q3) 72 (60, 76) 74 (66, 81) 0.1
Orthostatic hypotension, n (%) 7 (19) 9 (9) 0.1
Primary presenting symptom, n (%)
Breathlessness 29 (80.5) 53 (53.5)
Atrial ﬁbrillation/ﬂutter 0 (0) 10 (10)
Edema 0 (0) 8 (8)
Incidental ﬁnding 0 (0) 8 (8)
Syncope 1 (3) 6 (6)
Palpitations 0 (0) 3 (3)
Chest pain 2 (5.5) 3 (3)
Orthostatic hypotension 0 (0) 2 (2)
Frank hematuria 0 (0) 2 (2)
Carpal tunnel syndrome 0 (0) 1 (1)
Cough 0 (0) 1 (1)
Diarrhea 0 (0) 1 (1)
Dizziness 0 (0) 1 (1)
Chest sepsis 1 (3) 0 (0)
Lethargy 3 (8) 0 (0)
Continued
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Baseline Biochemical Evaluation
On univariate analysis (Table 1), there were no major
differences in biochemical markers of liver function, consis-
tent with the SAP scans, which showed no cases of hepatic
amyloid deposits in either group. There was signiﬁcantly more
proteinuria in the AL group, perhaps from renal amyloid
involvement, which was below the threshold of detection by
SAP scintigraphy. There was no difference in eGFR in patients
with proteinuria compared with those without. Three patients
with ATTRwt had underlying renal diseases associated with
>1 g of proteinuria; all other patients had <1 g of proteinuria
at baseline. The most signiﬁcant difference on univariate
analysis was in NT pro-BNP measurements. There was a
median of 714 pmol/L in the AL group and 317.5 pmol/L in
the ATTRwt group (P<0.001). Evidence of a plasma cell
dyscrasia was found in all patients with cardiac AL but also as
an incidental ﬁnding in 24.1% of patients with ATTRwt
(P<0.001).
Baseline Cardiac Investigations
On univariate analysis of ECG features, signiﬁcantly more
patients were in AF or atrial ﬂutter in the ATTRwt group, and
more patients had AV conduction abnormalities (Table 2).
Low QRS complexes were only seen in 27.3% of the AL
patients and 12.9% of the ATTRwt patients. There were
signiﬁcant differences between the 2 groups in several
echocardiographic features (Table 3). On univariate analysis,
patients with ATTRwt had signiﬁcantly thicker-walled hearts
than those in the AL group. Both groups had predominantly
diastolic dysfunction, most commonly grade III/IV, indicating
a restrictive ﬁlling pattern. The E/E was higher in the AL
group (median [Q1, Q3], 21.76 [15.7, 26.06] versus 15.81
[12.37, 17.91]; P≤0.001). Mitral valve deceleration time was
longer in the ATTRwt group (mean, 191.259.35 versus
147.942.46; P≤0.001; CI, 20.42 to 66.26), and the IVRT
was also higher in the ATTRwt group (mean, 87.2125.41
versus 74.3520.74; P=0.01; CI 2.68 to 23.03). Both groups
had relatively preserved ejection fractions.
Distinguishing Between Patients With Isolated AL
Amyloidosis and ATTRwt
We sought to identify baseline characteristics that could
distinguish between the 2 diagnoses. All patients in the AL
amyloidosis group had a detectable underlying plasma cell
dyscrasia, indicating that if no plasma cell dyscrasia could be
identiﬁed in this cohort, the diagnosis was ATTRwt. No
patients with ATTRwt had evidence of macroglossia, which
was purely an indicator of AL amyloidosis. A logistic
regression model was used on the remaining 47 patients
(25 patients with AL amyloidosis and 22 patients with
ATTRwt) who had a detectable plasma cell dyscrasia and no
macroglossia. There were no clinically relevant differences in
baseline characteristics in the excluded patients when
Table 1. Continued
AL (n=36) ATTRwt (n=99) P Value
NYHA class, n (%)
I 0 (0) 35 (35) <0.001
II 14 (38) 26 (26)
III 17 (47) 25 (25)
IV 5 (13) 6 (6)
Missing 0 (0) 7 (7)
Weight loss, n (%) 14 (38) 18 (18) 0.02
History of atrial ﬁbrillation, n (%) 6 (16) 43 (43) 0.004
History of ischemic heart disease, n (%) 4 (11) 27 (27) 0.06
Pacemaker, n (%) 2 (5.5) 13 (13) 0.4
Previous normal coronary angiogram, n (%) 8 (22) 12 (12) 0.2
Previous coronary artery bypass graft, n (%) 0 (0) 8 (8) 0.1
History of chest pain, n (%) 3 (8) 14 (14) 0.6
History of carpal tunnel syndrome, n (%) 3 (8) 48 (48) <0.01
History of lower-limb neuropathy, n (%) 3 (8) 9 (9) 1.00
Macroglossia or bruising, n (%) 9 (25) 0 (0) <0.001
AL indicates light-chain amyloidosis; ATTRwt, wild-type transthyretin amyloidosis; NT pro-BNP, N-terminal pro-B-type natriuretic peptide; Hb, hemoglobin; ALP, alkaline phosphatase;
GGT, Gamma-glutamyl transpeptidase; eGFR, estimated glomerular ﬁltration rate; NYHA, New York Heart Association.
*Either a detectable paraprotein or an abnormal free light-chain ratio.
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stratiﬁed by amyloid type. NT pro-BNP and age at diagnosis
were both associated with risk of ATTRwt. NT pro-BNP was
higher in patients with AL amyloidosis. The odds of having
ATTRwt reduced by 0.1% for every pmol/L unit increase in NT
pro-BNP (P=0.04). Patients with ATTRwt were older, with the
odds of ATTRwt increasing by 102% for every 1-year increase
in age (P=0.02). A further logistic regression analysis that
replaced actual age at diagnosis with age at diagnosis as a
binary variable (27 patients aged ≤70 years and 20 patients
aged >70 years) indicated that both the binary age variable
and NT pro-BNP at baseline were signiﬁcantly associated with
diagnosis (P=0.009 and P=0.03, respectively). Figure 1 shows
the probability of having ATTRwt amyloidosis in patients who
have isolated cardiac amyloidosis without macroglossia or
easy bruising with a detectable plasma cell dyscrasia in
patients above or below 70 years of age according to the NT
pro-BNP at baseline. Patients ≤70 years old were more likely
(P>0.5) to have ATTRwt than AL if the NT pro-BNP was
<183 pmol/L, and patients >70 years old with an NT pro-BNP
of <1420 pmol/L were more likely to have ATTRwt. Using this
combination of age and NT pro-BNP, the positive predictive
value was 90.0% and negative predictive value was 85.2%,
with a positive likelihood ratio of 10.2 and negative likelihood
ratio of 0.19. The area under the ROC curve was 0.98 (CI,
0.95 to 1.0), sensitivity 83.3%, and speciﬁcity 92%.
Patient Survival
Survival from diagnosis in patients with ATTRwt was signif-
icantly longer than for the cardiac-isolated AL group (log-rank
test, P=0.001). Median survival for patients with ATTRwt was
2.71 years and for cardiac AL amyloidosis patients, survival
was 0.87 years (Figure 2). Median survival from the onset of
symptoms was much longer than from diagnosis in the
ATTRwt group: 6.07 years compared with 1.7 years in the
cardiac AL group (log-rank test, P≤0.0001; Figure 3).
Factors at baseline that were associated with poorer
survival in the ATTRwt patients on univariate analysis were: a
positive troponin (median survival, 1.8 versus 4.6 years; log-
rank test, P=0.01) a pacemaker (median survival, 1.3 versus
4.06 years; log-rank test, P=0.002), and NYHA class (median
survival: class I, 4.58 years; class II, 4.06 years; class III,
2.08 years; and class IV, 1.31 years; log-rank test for trend,
P<0.001). These factors remained signiﬁcantly associated
with death in a Cox proportional hazards multivariable
analysis; however, because of the sample size and limited
number of events, the conﬁdence intervals showed inade-
quate precision, and therefore no absolute conclusions could
be drawn from the current patient numbers.
Thirty-two patients in the ATTRwt group died. The primary
causes of death reported on the death certiﬁcates were as
follows: 17 from congestive cardiac failure and 1 each from
complete heart block, hypertensive heart disease, ischemic
heart disease, ischemic stroke, old age, multiorgan failure,
renal failure, acute myeloid leukemia, mesothelioma, meta-
static lung cancer, urinary tract infection, and pneumonia. The
cause of death was unknown to us in 3 patients. Only 2
patients in the AL amyloidosis group developed extracardiac
amyloid; 1 patient had symptoms of progressive peripheral
neuropathy, and 1 patient developed end-stage renal failure.
Twenty-one (58%) died before their 6-month follow-up
appointment.
Discussion
ATTRwt amyloidosis is a slowly progressive disease of the
elderly whose incidence is unknown. ATTRwt amyloid has
been shown to deposit in the carpal tunnel.20 A recent series
has reported ATTRwt deposits in 34% of patients with
idiopathic carpal tunnel syndrome21 Connors et al22 recently
Table 2. Electrocardiography at Baseline
AL (n=34) ATTRwt (n=93) P Value
Rhythm, n (%)
Sinus 28 (82) 42 (45) 0.002
Atrial ﬁbrillation 4 (11) 36 (38)
Atrial ﬂutter 0 (0) 7 (7.5)
Paced 2 (5) 8 (8)
Mean voltage leads
II/III/AVF (mm)
5.43.6 2.92.9 0.4
Mean voltage leads
V4/V5/V6 (mm)
11.55.5 13.54.7 0.2
Low QRS complexes*
(N/%)
9 (27) 11 (13) 0.2
Any AV conduction
abnormality,* n (%)
14 (43) 50 (58) 0.2
Right bundle branch
block
1 (3) 14 (16)
Left bundle branch
block
2 (6) 17 (20)
First-degree heart
block
5 (15) 10 (11)
Bifascicular block 5 (15) 9 (10.5)
Junctional rhythm 1 (3) 0 (0)
QT interval, ms 40171.5 430.155.2 0.003
QTcB, ms 596.6745.0 478.753.3 0.2
T-wave inversion,
n (%)
18 (53) 37 (39) 0.2
AL indicates light-chain amyloidosis; ATTRwt, wild-type transthyretin amyloidosis;
AV, atrio-ventricular; QTcB, corrected QT.
*Percentage of patients who were not paced are displayed.
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reported that carpal tunnel syndrome was rare in patients
with ATTRwt cardiac amyloid. It has been suggested that
systemic deposition of TTR occurs years before the onset of
cardiac dysfunction.23,24 In our series, 48% of ATTRwt patients
gave a history of carpal tunnel syndrome that preceded the
onset of clinical symptoms of heart failure in 77%, a median of
8 years before the diagnosis of amyloidosis being made,
consistent with a slowly evolving disease. ATTRwt can be
found in other tissues aside from the myocardium and
wrist.25–27 Almost 4% of our patients presented with frank
hematuria or an incidental ﬁnding on bladder histology. No
patients have had amyloid detectable on radiolabeled 123I SAP
scintigraphy.
Figure 1. Predicted probability of wild-type transthyretin amyloi-
dosis (ATTRwt) in patients ≤70 or >70 years with a detectable
plasma cell dyscrasia by N-terminal pro-B-type natriuretic peptide
(NT pro-BNP).
Figure 2. Patient survival from diagnostic biopsy. Median survival
of patients with wild-type transthyretin amyloidosis from diagnostic
biopsy is 2.71 years compared with 0.87 years for patients with
isolated cardiac AL amyloidosis. Overall survival is signiﬁcantly
longer in the ATTRwt group (P=0.002 log-rank [Mantel–Cox] test). AL
indicates light-chain amyloidosis; ATTRwt, wild-type transthyretin
amyloidosis.
Table 3. Baseline Echocardiographic Parameters
AL ATTRwt P Value
IVSd, cm 1.50.2 (n=34) 1.70.3 (n=95) <0.001
LVPWd, cm 1.50.2 (n=34) 1.70.2 (n=95) <0.001
LVIDd, cm 4.20.4 (n=34) 4.40.6 (n=95) 0.1
LV ejection fraction, % 47.812.6 (n=34) 46.612.8 (n=95) 0.9
E/A ratio 2.61.3 (n=26) 2.41.0 (n=66) 0.9
E/EI (IQR) 21.8 (15.7, 26.1) (n=31) 15.8 (12.4, 17.9) (n=86) <0.001
MVdecT, ms 147.942.5 (n=31) 191.259.4 (n=91) <0.001
IVRT, ms 74.420.7 (n=31) 87.225.4 (n=79) 0.01
TDI wave lateral, ms 0.060.02 (n=20) 0.060.05 (n=70) 0.4
Grade of diastolic dysfunction, n (%)* (n=29) (n=76)
Normal 0 0.4
I 2 (7) 10 (13)
II 5 (17) 19 (25)
III/IV 22 (76) 47 (62)
AL indicates light-chain amyloidosis; ATTRwt, wild-type transthyretin amyloidosis; IVSd, interventricular septal thickness in diastole; LVPWd, left ventricular posterior wall thickness in
diastole; LV, left ventricular; E/A, doppler of transmitral inﬂow velocities measured at the tip of the mitral leaﬂets; E/EI, left sided ventricular ﬁlling pressures; IQR, interquartile range;
MVdecT, mitral valve deceleration time; IVRT, isovolumetric relaxation time; TDI, tissue Doppler imaging.
*Because of varying times at which echocardiography was performed, not all measures are reported in all patients.
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The apparent increase in the disease over the last couple
of years reﬂects an increase in the number of referrals to our
center. Although the total number of amyloid referrals has
risen, the proportion referred from cardiologists has vastly
increased. Thirty-seven percent of cases had amyloid sus-
pected on the basis of CMR ﬁndings. The use of sophisticated
cardiac imaging techniques such as CMR in elderly patients is
now more readily available, and as the population ages, the
prevalence of the disease may well be increasing.
Studies describing the natural history of the disease have
been limited to small numbers.11 This long-term follow-up
study of 102 patients with ATTRwt amyloidosis is, to our
knowledge, the largest study to date. Patients predominantly
presented with heart failure, although breathlessness was
generally less severe than in cardiac AL amyloidosis despite
greater left ventricular (LV) wall thickness. Patients with
ATTRwt amyloidosis had more arrhythmias than those with AL
and were more likely to have required pacing before
diagnosis. Our ﬁndings are consistent with those reported
by Rapezzi et al11 where patients with ATTRwt were found to
have the greater LV wall thicknesses than those with cardiac
AL and hereditary TTR amyloidosis and a higher incidence of
left bundle branch block. Low QRS complexes are widely
considered a marker of diagnosis of cardiac amyloidosis. In
this study the prevalence of this was lower than previously
described.28 Although low-voltage QRS complexes on the ECG
remain a potential indicator of cardiac amyloid, it is important
to note that normal-size complexes should not deter physi-
cians from considering a diagnosis of amyloid.
A marked survival difference between patients with ATTRwt
and cardiac AL amyloidosis has been reported before.11,22
Median survival in patients with ATTRwt was 2.71 years from
diagnosis compared with 0.87 years in the AL group. This is
even more striking when survival from symptom onset is
considered; the median survival in the ATTRwt group was
6.07 years, and this may be a more useful indicator for
patients who have been picked up early on in the course of
the disease or whose cardiac amyloid is an incidental ﬁnding.
The presence of a pacemaker was associated with shorter
survival from diagnosis. Clearly this does not necessarily
imply causality; indeed, it seems likely that patients with
conduction abnormalities necessitating a pacemaker are at
higher risk of sudden cardiac death. A recent study in familial
amyloid polyneuropathy reported that prophylactic pacemak-
ers prevented major cardiac events in 25% of patients.29
There is no speciﬁc literature on the role of implantable
cardiac deﬁbrillators in ATTRwt amyloidosis, but in the AL type
it seems that very careful patient selection is required, as
most sudden cardiac death is from pulseless electrical activity
that is not amenable to cardioversion.30
A positive troponin T at baseline was associated with
poorer survival. Suhr et al31 reported NT pro-BNP to be a
sensitive marker for diagnosing ATTR cardiomyopathy in
hereditary Val30Met patients. Recent data from Russo et al
suggested that both troponin and BNP are prognostic
indicators in ATTR amyloidosis. Troponin appeared to be a
stronger predictor (HR, 2.2; 95% CI, 1.4 to 3.5; P≤0.01)
compared with BNP (HR, 1.2; 95% CI, 1.1 to 1.4; P<0.01).32
Interestingly, higher baseline NT pro-BNP in our cohort was
not associated with poorer survival. Survival worsened with
increasing NYHA class on univariate analysis. In our study
echocardiographic features such as wall thickness and degree
of diastolic or systolic dysfunction did not affect survival.
Although LV wall thickness has been reported to be associ-
ated with survival in patients with cardiac amyloidosis,11 we
were unable to draw any deﬁnite conclusions in our patients
with ATTRwt because of inadequate numbers for analysis.
The combination of transthyretin amyloid on endomyocar-
dial biopsy and wild-type TTR gene sequencing is the gold
standard for diagnosing ATTRwt. Although endomyocardial
biopsy carries a low reported risk of complications of between
1% and 2%,33 some elderly patients are not keen to undergo
such an invasive investigation. Tissue from screening biopsies
such as abdominal fat and the rectum can be helpful in
diagnosing amyloid; however, false-negatives can occur
because of patchy amyloid deposition, and Connors et al22
recently reported that only 27% of fat aspirates in ATTRwt
were positive. When histological conﬁrmation is not possible,
clinicians must rely on a combination of clinical history,
imaging, and biochemical markers to come to a diagnosis.
99mTc-DPD scintigraphy has been shown to be a sensitive
Figure 3. Patient survival from onset of symptoms. Median survival
of patients with wild-type transthyretin amyloidosis from onset of
symptoms is 6.07 years compared with 1.7 years for patients with
isolated cardiac AL amyloidosis. Overall survival from symptoms is
signiﬁcantly longer in the ATTRwt group (P≤0.0001 log-rank [Mantel–
Cox] test). AL indicates light-chain amyloidosis; ATTRwt, wild-type
transthyretin amyloidosis.
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imaging technique in diagnosing cardiac transthyretin
amyloidosis.34–36 Studies are currently limited by small
numbers, but the technique appears to be highly speciﬁc for
transthyretin amyloidosis,37 and it is emerging as a helpful
diagnostic tool; however, the availability of the technique is
currently limited to centers within Europe.
The prevalence of MGUS in the general population is 5.3%
among those >70 years, rising to 7.5% among those
≥85 years.38 Twenty-four percent of patients with proven
ATTRwt in this series were found to have a detectable plasma
cell dyscrasia. This high prevalence highlights both that highly
sensitive techniques can detect incidental low-grade clones in
a large proportion of the elderly, although obviously this may
also induce bias with amyloidosis sought most diligently in
patients with a detectable clonal excess, and that the presence
of a clone cannot be used to diagnose AL-type amyloidosis
without further conﬁrmation. Clearly, the converse is also a
concern, although in this series all the patients with isolated
cardiac AL amyloidosis did have a detectable plasma cell
dyscrasia. Indeed, in our center cardiac biopsy-proven isolated
cardiac amyloidosis accounts for only 1.84% of patients with
systemic AL amyloidosis; although it has been reported that
6% of patients with AL amyloidosis have no detectable clone,1
our recent experience from the prospective ALCHEMY
cohort39 suggests that only 1 of 494 new patients with AL
amyloidosis seen at our center had no evidence of a plasma
cell clone on serum and urine investigations. One would
therefore predict that it is extremely rare for a patient with AL
amyloidosis to present with isolated cardiac disease and no
detectable clone, although this is theoretically possible.
A much more frequent clinical problem is differentiating
between the ATTRwt and AL types in elderly patients who
have isolated cardiac amyloid and an abnormal clone. Cardiac
biopsy remains the only deﬁnitive method of distinction, and
some patients are not prepared to undergo this invasive
procedure. In this study, despite excluding patients with
isolated cardiac amyloid and symptoms that are pathogno-
monic for AL amyloidosis such as macroglossia or easy
bruising,1 it was possible to estimate the risk of ATTRwt
amyloid in patients with a detectable monoclonal protein by
using a combination of age and NT pro-BNP. NT pro-BNP is
dependent on factors such as renal function, arrhythmias, and
ﬂuid balance. Although these factors all display colinearity
with NT pro-BNP, they were discarded on logistic regression
Cardiac imaging suggests amyloid 
Echocardiogram - mean leŌ ventricular wall thickness >12mm/ diastolic dysfuncƟon
Cardiac MRI – Late gadolinium enhancement
99mTc-DPD scinƟgraphy – uptake in the myocardium
Take a history for Pathognomonic features of AL Amyloidosis
• Capillary fragility resulƟng in easy bruising eg periorbital bruising
• Macroglossia
• Autonomic dysfuncƟon
• MulƟple solid organ involvement (Abnormal LFTs, renal funcƟon, proteinuria)
Check for evidence of a plasma cell dyscrasia
• M-protein on Plasma electrophoresis
• Urine for Bence Jones Proteins
• Serum free light chains
AL amyloidosis
(biopsy aﬀected organ)
Gene sequencing 
for hereditary 
transthyreƟn 
amyloid
TransthyreƟn amyloid
(fat biopsy or cardiac biopsy)
Wild type TransthyreƟn amyloid
(fat biopsy or cardiac biopsy)
Either wild type transthyreƟn 
amyloid or AL amyloidosis
(consider cardiac biopsy)
Age ≤ 70Age > 70
NT-proBNP <1420pmol/L
Greater probability of 
wild type transthyreƟn 
amyloid
NT-proBNP <183pmol/L
Greater probability of 
wild type transthyreƟn 
amyloid
NT-proBNP >183 pmol/L.
Greater probability of AL 
amyloidosis
NT-proBNP >1420 pmol/L
Greater probability of AL 
amyloidosis
PosNeg
Neg
Neg
NegPos Pos
Figure 4. Diagnostic algorithm for patients presenting with suspected cardiac amyloidosis based on cardiac imaging. Initial investigations
should include a comprehensive patient history and examination, investigations for an abnormal clone, and genotyping for hereditary transthyretin
amyloidosis. MRI indicates magnetic resonance imaging; AL, light-chain amyloidosis; NT pro-BNP, N-terminal pro-B-type natriuretic peptide.
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analysis, and NT pro-BNP remained a strong predictor of the
diagnosis of either an AL or ATTRwt assessment of a patient
with amyloidosis.
Conclusions
An accurate diagnosis of amyloid type in patients with
apparently cardiac-isolated disease is paramount. Cardiac AL
amyloidosis and ATTRwt are separate diseases with very
different outcomes and treatment. Survival in ATTRwt is far
superior to cardiac AL amyloidosis, and chemotherapy is
inappropriate in isolated ATTRwt. Troponin T, the need for a
pacemaker, and severe functional impairment (NYHA class IV
symptoms) are associated with poor outcome. We have
generated an algorithm that outlines the diagnostic process
once a patient is diagnosed with cardiac amyloid and uses a
patient’s age at diagnosis and level of NT pro-BNP to help to
distinguish between the 2 disease groups in patients with
isolated cardiac disease and a detectable plasma cell
dyscrasia (Figure 4); however, the gold standard is a histo-
logical diagnosis.
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